31 results about "Metabolic health" patented technology

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and / or the grain comprises a reduced level of SBEIIa enzyme activity and / or protein relative to wild-type grain.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30%.

A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and / or the grain comprises a reduced level of SBEIIa enzyme activity and / or protein relative to wild-type grain.

A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30%.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

A method of improving metabolic health in a mammalian subject in need of improvement in metabolic health includes reducing the mammalian subject's consumption of branched chain amino acids (BCAAs) by the mammalian subject consuming a reduced BCAA daily diet. Also included is a method of reducing a mammalian subject's consumption of BCAAs by the mammalian subject consuming a reduced BCAA meal replacement at least once per day. Also included is a method of feeding a mammalian subject in need of weight reduction by the mammalian subject consuming a low protein daily diet supplemented with leucine. Also included is a method of improving metabolic health in a mammalian subject in need of improvement in metabolic health by reducing the mammalian subject's consumption either histidine alone or of both phenylalanine and tyrosine by the mammalian subject consuming a reduced amino acid daily diet.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform receives patient data recorded during the current time period comprising food items consumed, medications taken, and symptoms experienced by the patient. The platform implements a machine-learned metabolic model to determine a metabolic state of the patient at a conclusion of the current time period by comparing a true representation of the metabolic state and a prediction of the metabolic state. The true representation and the prediction are determined based on the recorded biosignals and the recorded patient data, respectively. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve their metabolic state and provides the patient-specific treatment recommendation to the patient device for display to the patient.

The present disclosure provides methods for expanding TIL populations from fine needle aspirates (FN As) or small biopsies which contain low numbers of TILs, using the methods disclosed herein including in a closed system that leads to improved phenotype and increased metabolic health of the TILs in a shorter time period.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

Compositions for affecting the intestinal microbiome of a mammalian subject can include a pharmaceutically-acceptable carrier and greater than or equal to 1*104 PFU / mL or PFU / mg of bacteriophage having a tropism that includes an obesogenic and / or inflammatory bacterium associated with an intestinal microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating thebacteriophage from an environmental source, characterizing the bacteriophage, and combining the bacteriophage with the pharmaceutically acceptable carrier at greater than or equal to1*104 PFU / mL or PFU / mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics. Administering the disclosed compositions can reduce a concentration of obesogenic and / or inflammatory bacteria in the intestinal microbiome of the mammalian subject, promote or induce weight loss, reduce inflammation, support metabolic health, and / or support a healthy balance / diversity within the intestinal microbiome of the mammalian subject.

The present invention relates to a marker that can be used as aging biomarker. More specifically, the present invention relates to the analysis of nucleolar size as a biomarker for aging and metabolic health and its relation to the virtual age, or the life expectancy of animals, including humans. The aging biomarker of the invention can be used to study the effect of medication, food compounds and / or special diets on the wellness and virtual age, or the life expectancy of animals, including humans.

The invention discloses a bioactive peptide solid beverage for eliminating dampness and eliminating oedema and a preparation method of the bioactive peptide solid beverage. The beverage is prepared from the following raw materials in percentage by weight of 20-30% of isolated soy protein, 15-25% of isomaltooligosacharide, 15-20% of crystal sugar, 3-8% of fish collagen powder, 3-8% of resistant dextrin, 3-8% of chrysanthemum powder, 1-5% of soybean peptide powder, 1-5% of dandelion powder, 1-5% of rice bean powder, 1-5% of wheat oligopeptide, 1-5% of corn oligopeptide powder, 1-5% of wheat germpowder, 1-5% of konjaku flour, 0.5-1.5% of lotus leaf powder, 0.5-1.5% of coix seed powder, 0.5-1.5% of fingered citron powder, 0.5-1.5% of Chinese wolfberry fruit powder, 0.5-1.5% of villous amomumfruit powder, 1-5% of composite vitamins and 0.3-0.6% of silicon dioxide. The bioactive peptide solid beverage for eliminating dampness and eliminating oedema is convenient to carry and drink, has theefficacy of eliminating dampness, eliminating oedema, regulating body metabolism, being healthy and reducing fat, can effectively regulate mechanisms of human bodies after being drunk for a long term, and can achieve good health-preserving health-care effects.

The present invention discloses compositions containing digestive enzymes for the management and maintenance of metabolic health. Specifically, the invention discloses the use of digestive enzymes comprising α-amylase, lactase, lipase, cellulase and Neutral protease or Acid protease in weight management, reducing cholesterol levels, maintaining healthy gut and improving quality of life.

The invention discloses dietary food for treating malnutrition and a preparation method thereof. The raw materials of the dietary food include cooked millet powder, cooked soybean meal, a vitamin complexing agent and a mineral complexing agent. Through the proving of animal experiments, the dietary food can obviously improve developmental retardation, emaciation, low body weight and bowel functions caused by malnutrition, and can also improve metabolic health and inflammation; and therefore, the dietary food can be used for treating the malnutrition.

We disclose a method of detecting the metabolic health of a mammal, including a human, by determining whether a given animal is normal, pre-diabetic or diabetic through the determination of the levels of Wnt4 and Wnt3a proteins in the blood serum.

This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.

We disclose a method of detecting the metabolic health of a mammal, including a human, by determining whether a given animal is normal, pre-diabetic or diabetic through the determination of the levels of Wnt4 and Wnt3a proteins in the blood serum.

The invention relates to compositions and methods using a combination of at least one histidine or derivative thereof, at least one glycine or derivative thereof, and at least one additional agent selected from N-acetyl-cysteine, lysine, or arginine. An aspect of the invention is a method of promoting healthy fat metabolism and metabolic health in children at risk of developing insulin resistance and diabetes, promoting healthy lipolysis and use of fatty acid in metabolism, promoting healthy fat and adipocyte metabolism during puberty and adolescence, treating or preventing oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, or a condition associated with a reduced level of glutathione, by administering an effective amount of a combination of at least one glycine or derivative thereof, and lysine.

The invention discloses a plant-based coffee composition as well as a preparation method and application thereof, and belongs to the field of coffee products. The plant-based coffee composition comprises an edible medicinal plant A extracting solution, an edible medicinal plant B extracting solution and a coffee extracting solution, and the mass ratio of plant raw materials of the edible medicinal plant A extracting solution to the edible medicinal plant B extracting solution to the coffee extracting solution is that the edible medicinal plant A to the edible medicinal plant B to coffee beans is equal to (1-2): (6-10): (4-6), the content of ginsenoside in the edible medicinal plant A extracting solution is 4-6wt%, the content of vitamin C in the edible medicinal plant B extracting solution is 16-21mg / g, and the content of soluble solids in the coffee extracting solution is 0.7-1.38 wt%. The plant-based coffee composition disclosed by the invention is simple, natural and healthy in raw materials, has the functions of refreshing and improving metabolic health, and avoids common expressions such as insomnia, restlessness, excitation and tachycardia possibly caused by caffeine and the influence of unattractive teeth caused by coffee stain deposition.

The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and / or encrypting data.

A medical testing system comprises a housing, at least one magnet assembly configured around a probe configured to accept a human finger, formed in the housing wherein the at least one magnet assembly creates a permanent magnetic field around the probe, an RF signal generator configured to create a temporary magnetic field perpendicular to the permanent magnetic field in the housing, and an NMR coil assembly wherein a change in the permanent magnetic field induces a voltage in the NMR coil assembly.

This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.